Cadrenal Therapeutics Inc (CVKD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.00-5.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CVKD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CVKD — restructuring
Dated 2026-10-07
Other Events. On October 7, 2026, the Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions. The strategic review is at a pr…
Why it matters: Cash was about $4.2 million in early August, and the company said it could fund operations through Q1 2027. A shorter runway may limit trial plans.
Worry ifThe November 9 update shows cash below $4.2 million and says runway ends before Q1 2027, with no new funding in place.
Less concerning ifThe update shows new funding or partner cash that extends the stated runway beyond Q1 2027.
Why it matters: The company filed for Rare Pediatric Disease status for tecarfarin in Kawasaki disease. An FDA decision would show if this path has FDA support.
Watch forThe FDA gives tecarfarin Rare Pediatric Disease status. It is meant to prevent clots in children with Kawasaki disease.
Also watch forThe FDA denies the request, or the company says it remains unresolved with no stated next step.
Why it matters: The FDA agreed on the trial’s main outcome and placebo control. A cleared study plan is a key step toward testing CAD-1005 in HIT.
Supportive ifThe company files for or announces FDA clearance to start the Phase 3 trial. The trial uses the agreed endpoint and a placebo control.
Worry ifThe FDA asks for major protocol changes, or the company reports that the trial cannot start under the agreed plan.
Why it matters: The company needs outside funding to run large trials. A signed deal could bring funding or shift trial costs to a partner.
Supportive ifThe company announces a signed license, sale, development deal, or business combination. The deal has clear terms for at least one asset.
Worry ifThe company reports that its review ended without a deal. Or it gives no funding path before its stated cash runway ends.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$328 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $932 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,316 loss on $10,000 · 93.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.